152 related articles for article (PubMed ID: 8894618)
41. Selectivity of ligand binding to opioid receptors in brain membranes from the rat, monkey and guinea pig.
Clark MJ; Carter BD; Medzihradsky F
Eur J Pharmacol; 1988 Apr; 148(3):343-51. PubMed ID: 2898375
[TBL] [Abstract][Full Text] [Related]
42. Differential antagonism of U69,593- and bremazocine-induced antinociception by (-)-UPHIT: evidence of kappa opioid receptor multiplicity in mice.
Horan P; de Costa BR; Rice KC; Porreca F
J Pharmacol Exp Ther; 1991 Jun; 257(3):1154-61. PubMed ID: 1646325
[TBL] [Abstract][Full Text] [Related]
43. Identification and characterization of delta opioid binding sites in the bovine pineal.
Aloyo VJ
J Pharmacol Exp Ther; 1992 Jul; 262(1):292-7. PubMed ID: 1320688
[TBL] [Abstract][Full Text] [Related]
44. Mu- and delta-opioid receptor-mediated inhibition of adenylate cyclase activity stimulated by released endogenous dopamine in rat neostriatal slices; demonstration of potent delta-agonist activity of bremazocine.
Heijna MH; Hogenboom F; Portoghese PS; Mulder AH; Schoffelmeer AN
J Pharmacol Exp Ther; 1989 Jun; 249(3):864-8. PubMed ID: 2543814
[TBL] [Abstract][Full Text] [Related]
45. Ca2+ channel and adenylyl cyclase modulation by cloned mu-opioid receptors in GH3 cells.
Piros ET; Prather PL; Loh HH; Law PY; Evans CJ; Hales TG
Mol Pharmacol; 1995 May; 47(5):1041-9. PubMed ID: 7746271
[TBL] [Abstract][Full Text] [Related]
46. Quantitative analysis of multiple kappa-opioid receptors by selective and nonselective ligand binding in guinea pig spinal cord: resolution of high and low affinity states of the kappa 2 receptors by a computerized model-fitting technique.
Tiberi M; Magnan J
Mol Pharmacol; 1990 May; 37(5):694-703. PubMed ID: 2160061
[TBL] [Abstract][Full Text] [Related]
47. Properties of TAN-67, a nonpeptidic delta-opioid receptor agonist, at cloned human delta- and mu-opioid receptors.
Knapp RJ; Landsman R; Waite S; Malatynska E; Varga E; Haq W; Hruby VJ; Roeske WR; Nagase H; Yamamura HI
Eur J Pharmacol; 1995 Oct; 291(2):129-34. PubMed ID: 8566162
[TBL] [Abstract][Full Text] [Related]
48. Mechanism of clocinnamox blockade of opioid receptors: evidence from in vitro and ex vivo binding and behavioral assays.
Zernig G; Burke T; Lewis JW; Woods JH
J Pharmacol Exp Ther; 1996 Oct; 279(1):23-31. PubMed ID: 8858971
[TBL] [Abstract][Full Text] [Related]
49. Autoradiographic study of irreversible binding of [3H]beta-funaltrexamine to opioid receptors in the rat forebrain: comparison with mu and delta receptor distribution.
Liu-Chen LY; Li SX; Lewis ME
Brain Res; 1991 Mar; 544(2):235-42. PubMed ID: 1645609
[TBL] [Abstract][Full Text] [Related]
50. Nalbuphine: an autoradiographic opioid receptor binding profile in the central nervous system of an agonist/antagonist analgesic.
De Souza EB; Schmidt WK; Kuhar MJ
J Pharmacol Exp Ther; 1988 Jan; 244(1):391-402. PubMed ID: 2826773
[TBL] [Abstract][Full Text] [Related]
51. Spinal opioid receptors and adenosine release: neurochemical and behavioral characterization of opioid subtypes.
Cahill CM; White TD; Sawynok J
J Pharmacol Exp Ther; 1995 Oct; 275(1):84-93. PubMed ID: 7562600
[TBL] [Abstract][Full Text] [Related]
52. Differential cross-tolerance between analgesia produced by alpha 2-adrenoceptor agonists and receptor subtype selective opioid treatments.
Paul D; Tran JG
Eur J Pharmacol; 1995 Jan; 272(1):111-4. PubMed ID: 7713142
[TBL] [Abstract][Full Text] [Related]
53. Pharmacological characterization of the ameliorating effect on short-term memory impairment and antinociceptive effect of KT-90 in mice.
Hiramatsu M; Hoshino T; Kanematsu K
Behav Brain Res; 2005 May; 160(2):374-81. PubMed ID: 15863234
[TBL] [Abstract][Full Text] [Related]
54. Opiate binding in calf thalamic membranes: a selective mu 1 binding assay.
Clark JA; Houghten R; Pasternak GW
Mol Pharmacol; 1988 Sep; 34(3):308-17. PubMed ID: 2901663
[TBL] [Abstract][Full Text] [Related]
55. Distinct antinociceptive actions mediated by different opioid receptors in the region of lamina I and laminae III-V of the dorsal horn of the rat.
Hope PJ; Fleetwood-Walker SM; Mitchell R
Br J Pharmacol; 1990 Oct; 101(2):477-83. PubMed ID: 2175238
[TBL] [Abstract][Full Text] [Related]
56. Electrophysiological demonstration of mu, delta and kappa opioid receptors in the ventral pallidum.
Mitrovic I; Napier TC
J Pharmacol Exp Ther; 1995 Mar; 272(3):1260-70. PubMed ID: 7891342
[TBL] [Abstract][Full Text] [Related]
57. Evaluation of a series of N-alkyl benzomorphans in cell lines expressing transfected delta- and mu-opioid receptors.
Abood ME; Noel MA; Carter RC; Harris LS
Biochem Pharmacol; 1995 Sep; 50(6):851-9. PubMed ID: 7575648
[TBL] [Abstract][Full Text] [Related]
58. Binding to mu and delta opioid sites but not kappa sites is inhibited by Fab fragments from a monoclonal antibody directed against the opioid receptor.
Bidlack JM
NIDA Res Monogr; 1986; 75():21-4. PubMed ID: 2828974
[TBL] [Abstract][Full Text] [Related]
59. Action at the mu receptor is sufficient to explain the supraspinal analgesic effect of opiates.
Fang FG; Fields HL; Lee NM
J Pharmacol Exp Ther; 1986 Sep; 238(3):1039-44. PubMed ID: 3018217
[TBL] [Abstract][Full Text] [Related]
60. Chronic effect of [D-Pen2,D-Pen5]enkephalin on rat brain opioid receptors.
Tao PL; Tsai CL; Chang LR; Loh HH
Eur J Pharmacol; 1991 Aug; 201(2-3):209-14. PubMed ID: 1665782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
